Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction

Journal of the American College of Cardiology

Volumn 38, Issue 2, 2001, Pages 436-442

  Stanek, Brigitte ^a   Frey, Bernhard ^a   Hülsmann, Martin ^a   Berger, Rudolf ^a   Sturm, Barbara ^a   Strametz Juranek, Jeanette ^a   Bergler Klein, Jutta ^a   Moser, Petra ^a   Bojic, Anja ^a   Hartter, Engelber ^a   Pacher, Richard ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIG ENDOTHELIN 1; BIG ENDOTHELIN 2; BIG ENDOTHELIN 3; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; NEUROHORMONE; NORADRENALIN; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SURVIVAL;

ADRENERGIC BETA-ANTAGONISTS; ATENOLOL; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; DOUBLE-BLIND METHOD; ENDOTHELIN-1; ENDOTHELINS; FEMALE; HEART FAILURE, CONGESTIVE; HORMONES; HUMANS; MALE; MIDDLE AGED; NOREPINEPHRINE; PLACEBOS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN PRECURSORS; RANDOM ALLOCATION; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0034894106     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(01)01383-3     Document Type: Article

References (28)

1. Localization and mechanisms of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure
2. Plasma proatrial natriuretic factor is predictive of clinical status in patients with congestive heart failure
3. Comparison of atrial natriuretic peptide, B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction
4. The relative value of the natriuretic peptides as markers for detecting abnormal ventricular structure and function
5. Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators
6. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction
7. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-ProBNP): A new marker of cardiac impairment
8. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure. Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction
9. Prognostic impact of big endothelin-1 plasma concentrations as compared to invasive hemodynamic evaluation in severe heart failure
10. Value of cardiopulmonary exercise testing big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure
11. Prognostic value of hemodynamic versus big endothelin measurements during chronic intravenous therapy in advanced heart failure patients
12. Changes in plasma endothelin-1 reflect clinical response to β-blockade in chronic heart failure
13. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction
14. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: Randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy
15. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations
16. Effect of beta-1 blockade with atenolol on progression of heart failure in patients pretreated with high-dose enalapril
17. Neurohumoral changes in patients with heart failure treated chronically with beta-blockers
18. Effects of bucindolol in heart failure
19. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: A randomized double-blind, placebo-controlled study
20. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart
21. Acute effects of β1-selective and nonselective β-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure
22. The effects of moxonidine, a novel imidazoline, on plasma norepinephrine in patients with congestive heart failure
23. The effects of chronic, sustained-release moxonidine therapy on clinical and neurohumoral status in patients with heart failure
24. Evolving trends in the epidemiologic factors of heart failure: Rationale for preventive strategies and comprehensive disease management
25. Beta-blockers reduce the release and synthesis of endothelin-1 in human endothelial cells
26. Cardiac natriuretic peptides for diagnosis and risk stratification in heart failure: Influences of left ventricular dysfunction and coronary artery disease on cardiac hormone activation
27. BNP gene expression is specifically modulated by stretch and ET-1 in a new model of isolated rat atria
28. Vasodilatory effects of B-type natriuretic peptide are impaired in patients with chronic heart failure